Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia

SCHIZOPHRENIA RESEARCH

卷:141

Article

Jenko, Kimberly J.¹  Hirvonen, Jussi¹  Henter, Ioline D.¹  Anderson, Kacey B.¹  Zoghbi, Sami S.¹  Hyde, Thomas M.^2,3  Deep-Soboslay, Amy²  Innis, Robert B.¹  Kleinman, Joel E.² 

[1] NIMH, Mol Imaging Branch, NIH, Bethesda, MD 20892 USA

[2] NIMH, Clin Brain Disorders Branch, NIH, Bethesda, MD 20892 USA

[3] Lieber Inst Brain Dev, Baltimore, MD 21205 USA

关键词: Cannabinoid;    CB1;    Schizophrenia;    Dorsolateral prefrontal cortex;    [H-3]MePPEP;   

DOI  :  10.1016/j.schres.2012.07.021

来源: Elsevier

【 摘 要 】

This study sought to determine whether cannabinoid-1 (CB1) receptor binding was altered in the postmortem dorsolateral prefrontal cortex (DLPFC) of individuals with schizophrenia (schizophrenia; n = 47) compared to controls (n = 43). The CB1 receptor inverse agonist radioligand [H-3]MePPEP was used to measure specific binding to CB1 receptors. The specific binding of [H-3]MePPEP to CB1 receptors was 20% higher in patients with schizophrenia than in controls. Power analyses suggested that 53 subjects per group would be needed to detect a similar difference in vivo with positron emission tomography (PET) and the structurally related inverse agonist radioligand [F-18]FMPEP-d(2) (80% statistical power, p<0.05). Published by Elsevier B.V.

【 授权许可】

Free